

Letter to Our Shareholders

August 2021

Q2 2021

Dear Shareholders,

We are excited to share our progress with you in our first quarterly shareholder letter as a public company. Last month, we completed our business combination with Rodgers Silicon Valley Acquisition Corp. (RSVAC) and our listing on Nasdaq (ENVX). This transaction brought in gross proceeds of approximately \$405 million (\$230 million from RSVAC's trust account and \$175 million from a concurrent PIPE offering) and net proceeds of \$382 million. We plan to use these funds to scale-up two advanced Lithium-ion battery cell production facilities to meet the demands of our world-class customers. We welcome our new shareholders and look forward to sharing our progress in the quarters and years ahead.

We are committed to creating the first facility in the world to be capable of volume production of advanced Lithium-ion batteries with a 100% active silicon anode using a 3D cell architecture. During the quarter, the U.S Department of Energy released the "National Blueprint for Lithium Batteries 2021-2030." According to the report "[m]aintaining and expanding lithium cell and battery manufacturing capability here in the U.S. — as well as in allied and partner countries — is critical to U.S. national security and is essential to developing resilient defense supply chains not under threat from near-peer adversaries." We believe Enovix is well positioned to meet these needs with our U.S-based manufacturing footprint.

During the quarter, we were able to take receipt of the key equipment for our first production line at our Fab-1 facility in Fremont, California, despite the current global supply chain disruptions. This required a heroic effort on the part of our team, including a crucial decision to charter an Antonov An-124, one of the world's largest cargo planes, to fly over 60 tons of manufacturing equipment from Asia to San Francisco International Airport. We believe that this decision may have avoided delays of up to three months in the buildout of our Fremont production facility. Going the extra mile to stay on schedule has been extremely well-received by our customers, who are counting on us to deliver batteries with record energy densities.

On that note, we shipped final technology qualification samples from our pilot production line to key customers during the quarter. These samples represent the final configuration of the battery we have designed for these customers and met the product requirements that permitted us to move to the next stage of qualification. In the fourth quarter of 2021, we plan to ship production qualification samples from the production line in Fremont. These are important steps ahead of our expectation of beginning production in Q1 2022 and achieving first product revenue in Q2 2022.

We are excited about our recent contract award announcement to demonstrate our batteries for the U.S. Army in conjunction with Inventus Power. We believe that the total U.S. wearable military battery market is approximately \$350 million annually based on currently established military programs.

Supporting our factory scale-up, we are currently experiencing robust demand for our advanced batteries. The potential value of a full year of production from our design wins and active designs reached \$292 million at the end of the second quarter, which exceeds the anticipated revenue capacity of Fab-1. We are accelerating efforts throughout the company to scale including:

- 1) Talent acquisition, hiring, and training
- 2) Factory capacity
- 3) Design capacity
- 4) Investments in intellectual property
- 5) Creating a global footprint to support our customers



Scorecard

As we evolve from a company focused predominantly on R&D to a company capable of volume production and commercialization, we believe shareholders should evaluate our progress across five key areas:

Category	Milestone
1. Technology and Products	EX-1: 900 Wh/L energy density 2022 EX-2: 1,030 Wh/L energy density 2023 EX-3: 1,255 Wh/L energy density 2025
2. Manufacturing and Scale-Up	Fab-1: First revenue Q2 2022 Fab-2: First revenue Q2 2023
3. Commercialization	Progress funnel to revenue
4. Market Expansion	Broaden end market applications
5. Financials	\$1 billion+ annualized revenue by Q425 with 50% GM and 30% EBIT

1. Technology & Products

We shipped technology qualification samples to customers in the quarter, which is an important step on our way to delivering batteries in the EX-1 node from our automated production line at Fab-1 in Fremont.

Additionally, we have met key battery performance specifications for two of our lead customers. These include metrics such as energy density, cycle life at multiple temperatures, swelling, calendar life, and capacity.

2. Manufacturing and Scale-Up

In the quarter we were able to install and begin qualifying our first production line at our headquarters in Fremont. This line includes a combination of Enovix-designed proprietary equipment from tier one U.S.-based factory automation vendors as well as standard battery industry production equipment. This equipment incorporates our proprietary laser patterning, stacking, and constraining processes that uniquely manage the expansion of a 100% active silicon anode, replacing the traditional winding processes found in conventional Li-ion cell manufacturing.

With the equipment for Line 1 installed, our factory is now undergoing qualification. The first step in this process is a site acceptance test to confirm the individual pieces of equipment are meeting performance requirements. This follows factory acceptance testing already performed at the vendor's facility before taking delivery. The second step is a characterization process, or tool and process bring-up. This is a rigorous phase gate process developed and effectively used by several of our strategic partners and members of our management team to successfully scale up multiple high-volume production factories. To lead this effort, we have added Boris Bastien as Vice President of Operations to our executive management team. Bastien's most recent position was General Manager of SunPower's Fab4 in the Philippines.



3. Commercialization

We are seeing robust customer demand across multiple end markets. Our revenue funnel reached \$1.17 billion at the end of Q2 2021. The funnel metric comprises the potential value of a full production year for all projects across three stages: 1) engaged opportunities; 2) active designs; and 3) design wins. Within the funnel, active designs and design wins reached \$292 million. We are gratified by this level of endorsement, considering that it is occurring before Fab-1 is even in production.

In addition, we announced today that we have signed a Master Purchase Agreement and a Cooperation Agreement with a California-based technology leader focused initially on the wearable device space. Under terms of the agreements, Enovix will receive a manufacturing capacity reservation fee and pre-payments totaling \$3.5 million over the next 12 months. The total agreements are valued at up to \$20 million with commercialization scheduled to begin in 2025.

Last, we have added to our marketing organization and today are launching a new campaign – "Just in Time for the Future" that emphasizes the powerful role our batteries can play in enabling innovations across multiple industries.

Engaged Opportunities

Engaged customer has determined that our battery is applicable to their product and is evaluating our technology.



Active Designs + Design Wins

Active Design: Customer completed technology evaluation; identified end-product; begun design work

Design Win: Customer has funded a custom battery design or qualification of standard battery for a formally approved product that will use an Enovix 3D cell.

\$1.17B Revenue Funnel

Value of Full Production Year for all Projects

4. Market Expansion

We recently announced a contract to demonstrate our batteries for the U.S. Army in conjunction with Inventus Power. The Defense market is a great fit for Enovix on several levels:

- 1) A secure domestic source of supply is valued.
- 2) Soldiers need smaller and lighter batteries given that today they carry more than 60 pounds of gear, of which 15 pounds are batteries.
- 3) It is a market that prioritizes safety and product robustness and has rigorous testing standards.

We also continued our efforts during the quarter to demonstrate the applicability of our technology for EVs. We commissioned a study by a team of industry leading battery module designers to evaluate the advantages of our cell design for an EV module. The study confirmed the potential advantages Enovix brings to that market in the form of:

- 1) Higher energy density.
- 2) Excellent thermal properties, enabling fast charge advantages
- 3) Reduced module form factor and simpler, smaller electrical and thermal management sub-systems.

We look forward to addressing this market with our unique cell architecture in the years ahead.

5. Financials

We remain on track to deliver our first product revenue in 2022 and scale up in the years thereafter. Based on the strength of our revenue funnel, we see a favorable demand picture supporting our goal to exit 2025 with over \$1 billion of annualized revenue. It is also worth noting that our recent agreement with a wearable device customer confirmed our pricing model and the value of our energy density advantages.



Company Strategy

Our accomplishments in the second quarter moved us closer to delivering batteries with record energy densities for industry-leading customers in mobile electronics in 2022 We are targeting this market initially for several reasons:

- 1) Product designers demand high energy densities, which allow them to add features, functionality and create new form factors.
- 2) Batteries often make up a small fraction of the cost of the device, which speeds adoption in premium products.
- 3) Consumer electronics design cycles and qualification cycles are significantly shorter than in other applications such as automotive, thus enabling us to quickly get to volume production and revenue.

Our near-term focus is on the following market applications: wearables (smartwatches, AR/VR and headsets), computing and mobile communications. We estimate the total addressable market for Lithiumion batteries in these markets to be \$13 billion by 2025. We are actively sampling to potential customers across all three of these markets and have design wins in each. We believe this strategy will allow Enovix to deliver energy densities years ahead of the competition and provide a meaningful head start to reach scale and benefit from manufacturing learning curves.



In **wearables**, we are seeing a trend toward more feature-packed smartwatches, particularly to enable health and fitness monitoring. With each sensor that is added to track a physiological trait, there is a corresponding need for more energy. In addition, product designers want to make devices more "invisible" to the end user, which means smaller and lighter form factors. Our batteries enable

these features. As a result, we are engaged with multiple leading brands and several exciting new entrants.

We also have multiple potential customers targeting our batteries for Augmented Reality (AR) devices. This is a nascent category today, but several leading brands in consumer electronics, software and social media are investing significant resources in what they believe is the next mass market computing platform, following the PC and the smartphone.



In **computing**, there is a push in the industry led by our early investor Intel for laptop PCs to have "always-on" capability with all-day battery life. We believe we are well positioned to support this vision with our products and are seeing strong interest from leading laptop OEMs. These

OEMs are well-represented in our revenue funnel.



In **mobile communications**, OEMs want to increase the utilization of 5G radios and AI processing on the edge. These features place tremendous strain on device power budgets, driving strong interest in our batteries in this category. We also target enterprise class devices such as handheld devices used in retail, and land mobile radios

(LMR) which often need to remain charged for multiple first responder shifts. These devices are also increasingly taking on the complex features of a modern smartphone, with similar high-power needs. Our company is well-positioned to satisfy these demands and we have multiple active engagements across this category within our funnel.

We believe our focus on these initial categories will prepare us to address the electric vehicle (EV) battery opportunity by 2025. Scaling production is no small task and requires continuous improvement in throughput and yield. We believe becoming a profitable high-volume manufacturer of mobile electronics batteries de-risks our entry into the EV space. In parallel, we are actively carrying out multiple projects to address the EV market. This includes sampling batteries to Auto OEMs and work on our three-year grant with the U.S. Department of Energy to develop batteries featuring our silicon anode paired with EV-class cathode materials.



Outlook

Enovix expects to make meaningful progress toward our goal of starting production in Q1 2022 with product revenue in Q2 2022. With the proceeds from the SPAC merger and associated PIPE offering, we are well-capitalized and remain on track to fund our plan.

For full-year 2021 we expect to use between \$110 million and \$120 million of free cash flow with roughly half coming from capital expenditures, as we accelerate efforts to scale across multiple areas, including:

- 1) Talent acquisition and hiring. We have added 55 employees since the beginning of the year to bring our total to 184 as of June 30, 2021. In addition, we have supplemented our team with 62 contractors and temporary employees to assist in the bring up of Fab-1.
- 2) Factory capacity. We are investing to support the capacity ramp of Fab-1 including accelerating purchases and delivery of certain equipment in response to extended lead times in the supply chain..
- **3) Design capacity.** We are increasing our capacity for new designs and custom cell development in response to increasing demand and an expanding customer base.
- **4) Investments in intellectual property.** We are significantly expanding and accelerating our patent portfolio efforts to further protect our unique 3D architecture globally.
- 5) Creating a global footprint to support our customers. We are building out infrastructure to support a global customer base, including sales and customer support.

Summary

Our work in this first half of 2021 has been productive, and we have positioned our company to begin volume production of advanced Li-Ion batteries for delivery to category-leading customers in 2022. We are proud of our team's execution toward the creation of our first-of-a-kind production line.

Simply put, the world's next-generation products are starved for higher energy density batteries. Our team is focused on making a step change in energy density a reality.

As a result of our business combination with RSVAC, we are entering the second half of this year with significant financial strength, one that we will use to expand our revenue funnel, create two efficient high-volume manufacturing Fabs, and continue to develop batteries with unparalleled energy density.







Steffen Pietzke, CFO

Quarterly Conference Call and Webcast

Tuesday, August 10 / 2 p.m. PT / 5 p.m. ET

IR WEBSITE: ir.enovix.com

DIAL-IN: 1-833-865-1567, passcode: 9483164



Enovix Corporation

Consolidated Balance Sheets

(In Thousands, Except Share and per Share Amounts)

	June 30, 2021	De	ecember 31, 2020
Assets			
Current assets:			
Cash and cash equivalents	\$ 4,951	\$	29,143
Deferred contract costs	4,280		2,955
Prepaid expenses and other current assets	1,967		946
Total current assets	11,198		33,044
Property and equipment, net	 50,701		31,290
Operating lease, right-of-use assets	6,897		_
Deferred contract costs, non-current	_		495
Deferred transaction costs	5,725		_
Other assets, non-current	 141		135
Total assets	\$ 74,662	\$	64,964
Liabilities, Convertible Preferred Stock and Stockholders' Deficit	 		
Current liabilities:			
Accounts payable	\$ 5,458	\$	2,083
Accrued expenses	4,721		1,999
Accrued compensation	1,914		1,268
Deferred revenue	5,495		5,410
Secured promissory note	14,932		_
Other liabilities	710		108
Total current liabilities	 33,230		10,868
Deferred rent, non-current	_		1,567
Convertible preferred stock warrants	_		15,995
Operating lease liabilities, non-current	9,447		_
Deferred revenue, non-current	1,100		85
Other liabilities, non-current	265		233
Total liabilities	44,042		28,748
Commitments and Contingencies (Note 7)			
Convertible preferred stock, \$0.001 par value			
Authorized shares of 334,713,204; issued and outstanding shares of 334,531,360			
and 324,370,424; and aggregate liquidation preference of \$222,799 and \$205,372			
as of June 30, 2021 and December 31, 2020, respectively	222,933		202,056
Stockholders' deficit:			
Common stock, \$0.001 par value; authorized shares of 497,000,000; issued and			
outstanding shares of 104,597,618 and 93,986,381 as of June 30, 2021 and			
December 31, 2020, respectively	70		65
Additional paid-in-capital	45,363		41,373
Accumulated deficit	 (237,746)		(207,278)
Total stockholders' deficit	(192,313)		(165,840)
Total liabilities, convertible preferred stock and stockholders' deficit	\$ 74,662	\$	64,964

Enovix Corporation

Condensed Consolidated Statements of Operations (Unaudited)

(In Thousands, Except Share and per Share Amounts)

	Three Months Ended June 30,		Six Months En			nded June 30,	
		2021	2020		2021		2020
Operating expenses:							
Cost of revenue	\$	112	\$ 858	\$	1,743	\$	1,229
Research and development		9,523	3,230		15,112		5,635
Selling, general and administrative		4,548	1,280		8,709		2,280
Total operating expenses		14,183	5,368		25,564		9,144
Loss from operations		(14,183)	(5,368)		(25,564)		(9,144)
Other income (expense):							
Change in fair value of convertible							
preferred stock warrants		_	209		(4,781)		275
Issuance of convertible preferred stock							
warrants		_	_		_		(1,476)
Change in fair value of convertible							
promissory notes			_				(2,422)
Interest expense		(135)	_		(135)		(107)
Other income, net		15	9		12		42
Total other (expense) income, net		(120)	218		(4,904)		(3,688)
Net loss	\$	(14,303)	\$ (5,150)	\$	(30,468)	\$	(12,832)
	-	<u> </u>					•
Net loss per share, basic and diluted	\$	(0.21)	\$ (0.09)	\$	(0.45)	\$	(0.21)
Weighted average number of common		` '	(11)		, , ,		, ,
shares outstanding, basic and diluted		69,029,099	60,315,795		67,828,958		60,015,903
<u> </u>							



Enovix Corporation

Condensed Consolidated Statements of Cash Flows (Unaudited)

(In Thousands)

Adjustments to reconcile net loss to net cash used in operating activities 375 289 Depreciation 3,675 116 Changes in fair value of convertible preferred stock warrants 4,781 (275 Issuance of convertible preferred stock warrants (non-cash) — 1,476 Change in fair value of convertible promissory notes — 2,422 Interest expense (non-cash) — 107 Changes in operating assets and liabilities: — 107 Prepaid expenses and other assets 493 9 Deferred contract costs (693) (1,361 Accounts payable 3,904 (154 Accrued expenses and compensation 1,592 237 Deferred revenue 1,100 155 Other liabilities 99 397 Net cash used in operating activities: — (20,573) (11,543 Net cash flows from investing activities: — 39,213 Purchase of property and equipment (20,573) (11,543 Net cash used in investing activities (20,573) (11,543 Procee		Six Months Ended June 30,			June 30,
Net loss Adjustments to reconcile net loss to net cash used in operating activities Depreciation 375 288 Stock-based compensation expense Changes in fair value of convertible preferred stock warrants Issuance of convertible preferred stock warrants (non-cash) Change in fair value of convertible promissory notes Interest expense (non-cash) Change in fair value of convertible promissory notes Interest expense (non-cash) Changes in operating assets and liabilities: Prepaid expenses and other assets Prepaid expenses and other assets Accounts payable Accounts payab			2021		2020
Adjustments to reconcile net loss to net cash used in operating activities Depreciation 375 288 Stock-based compensation expense 3,675 116 Changes in fair value of convertible preferred stock warrants (non-cash) — 1,476 Change in fair value of convertible promissory notes — 2,422 Interest expense (non-cash) — 107 Changes in fair value of convertible promissory notes — 2,422 Interest expense (non-cash) — 107 Changes in fair value of convertible promissory notes — 107 Changes in operating assets and liabilities: Prepaid expenses and other assets — 493 — 91 Deferred contract costs — (693) — (1,361 Accounts payable — 3,904 — (154 Accrued expenses and compensation — 1,592 — 237 Deferred revenue — 1,100 — 155 Other liabilities — 99 — 397 Net cash used in operating activities — 99 — 397 Net cash used in operating activities: Purchase of property and equipment — (20,573) — (11,543 Net cash used in investing activities — 20,573 — (11,543 Net cash used in investing activities — 39,213 Proceeds from issuance of convertible preferred stock, net — 39,213 Proceeds from exercise of convertible preferred stock warrants — 39,213 Proceeds from mexercise of convertible preferred stock warrants — 39,213 Repurchase of unvested restricted common stock — 10,01 — 10,628 Proceeds from secured promissory notes and converted promissory notes — 14,910 — 1,628 Repurchase of unvested restricted common stock — 10,03 — 10,628 Repurchase of unvested restricted cash, beginning of period — 29,218 — 10,301 Cash and cash equivalents, and restricted cash, beginning of period — 29,218 — 10,301 Supplemental cash flow data (Non-cash): Accrued purchase of tronsective dequipment — \$ 2,298 \$ 5,053 Accrued purchase of tronsective through conversion of promissory notes to convertible preferred stock — 8,073 Externed purchase of transaction costs — 2,133 — 6,000 Conversion of promissory notes to convertible preferred stock — 8,073	Cash flows from operating activities:				
Depreciation 375 289	Net loss	\$	(30,468)	\$	(12,832)
Stock-based compensation expense Changes in fair value of convertible preferred stock warrants Issuance of convertible preferred stock warrants (non-cash) Change in fair value of convertible promissory notes Interest expense (non-cash) Changes in operating assets and liabilities: Prepaid expenses and other assets Prepaid expenses and other assets Prepaid expenses and other assets Prepaid expenses and compensation Deferred contract costs South Issuance of convertible preferred stock warrants Other liabilities Prepaid expenses and compensation Accounts payable Accrued expenses and compensation I,592 237 Deferred revenue I,100 155 Other liabilities Purchas of no perating activities Purchase of property and equipment Net cash used in operating activities Purchase of property and equipment Proceeds from investing activities Proceeds from investing a	Adjustments to reconcile net loss to net cash used in operating activities				
Changes in fair value of convertible preferred stock warrants (non-cash) — 1,476 Change in fair value of convertible promissory notes — 2,422 Interest expense (non-cash) — 107 Changes in operating assets and liabilities: Prepaid expenses and other assets Prepaid expenses and other assets (693) (1,361 Accounts payable 3,904 (154 Accrued expenses and compensation 1,592 237 Deferred revenue 1,100 155 Other liabilities 99 397 Net cash used in operating activities (20,573) (11,543 Ret cash used in operating activities: Purchase of property and equipment (20,573) (11,543 Net cash used in investing activities: Proceeds from investing activities: Proceeds from exercise of convertible preferred stock, net — 39,213 Proceeds from the exercise of stock options Repurchase of unvested restricted common stock (10) — Proceeds from secured promissory notes and converted promissory notes and cash equivalents, and restricted cash Cash and cash equivalents, and restricted cash (24,142) (19,382 Ret cash provided by financing activities (3,592) — Net cash provided by financing activities (10) — Proceeds from secured promissory notes and converted promissory notes (3,592) — Net cash provided by financing activities (11,573) (11,543) Repurchase of unvested restricted cash, end of period (24,142) (19,966 Cash and cash equivalents, and restricted cash (24,142) (19,966 Cash and cash equivalents and restricted cash (24,142) (19,966 Cash and cash equivalents, and restricted cash (24,142) (19,966 Cash and cash equivalents and restricted cash (24,142) (19,966 Cash and cash equivalents and restricted cash (24,142) (19,966 Cash and cash equivalents and restricted cash (24,142) (19,966 Cash and cash equivalents and restricted cash (24,142) (19,966 Cash and cash equivalents and restricted cash (24,142) (19,966 Cash and cash equivalents and restricted cash, end of period (24,142) (19,966 Cash and cash equivalents and restricted cash, end of period (24,142) (19,966 Cash and cash equivalents and restricted cash, end of period (24,142) (19,	Depreciation		375		289
Issuance of convertible preferred stock warrants (non-cash) — 1,476 Change in fair value of convertible promissory notes — 2,422 Interest expense (non-cash) — 107 Changes in operating assets and liabilities: — 107 Prepaid expenses and other assets 493 91 Deferred contract costs (693) (1,361 Accounts payable 3,904 (154 Accrued expenses and compensation 1,592 237 Deferred revenue 1,100 155 Other liabilities 99 397 Net cash used in operating activities (15,142) (9,332 Cash flows from investing activities (20,573) (11,543 Net cash used in investing activities (20,573) (11,543 Net cash used in investing activities (20,573) (11,543 Net cash used in investing activities (20,573) (11,543 Net cash flows from insuance activities (20,573) (11,543 Recash flows from insuance of convertible preferred stock, net — 39,213 Proceeds from i	Stock-based compensation expense		3,675		116
Change in fair value of convertible promissory notes Interest expense (non-cash) — 107 Changes in operating assets and liabilities: Prepaid expenses and other assets Prepaid expenses and other assets Accounts payable Accounts payable Account spayable Account sp	Changes in fair value of convertible preferred stock warrants		4,781		(275)
Interest expense (non-cash) — 107 Changes in operating assets and liabilities: 9 Prepaid expenses and other assets 493 91 Deferred contract costs (693) (1,361 Accounts payable 3,904 (154 Accrued expenses and compensation 1,592 237 Deferred revenue 1,100 155 Other liabilities 99 397 Net cash used in operating activities (15,142) (9,332 Cash flows from investing activities: (20,573) (11,543 Net cash used in investing activities (20,573) (11,543 Cash flows from investing activities 1,042 - Proceeds from exercise of convertible preferred stock warrants 102	Issuance of convertible preferred stock warrants (non-cash)		_		1,476
Changes in operating assets and liabilities: Prepaid expenses and other assets Prepaid expenses and compensation Proceed expenses and compensation Proceeds from investing activities Purchase of property and equipment Proceeds from investing activities Proceeds from exercise of convertible preferred stock, net Proceeds from exercise of convertible preferred stock warrants Proceeds from exercise of convertible preferred stock warrants Proceeds from secured promissory notes and converted promissory notes Proceeds from secured promissory notes and converted promissory notes Proceeds from exercise of sombination share issuance costs Payments of Business Combination	Change in fair value of convertible promissory notes		_		2,422
Prepaid expenses and other assets 493 91 Deferred contract costs (693) (1,361 Accounts payable 3,904 (154 Accrued expenses and compensation 1,592 237 Deferred revenue 1,100 155 Other liabilities 99 397 Net cash used in operating activities (15,142) (9,332 Cash flows from investing activities (20,573) (11,543 Net cash used in investing activities - 39,213 Proceeds from issuance of convertible preferred stock, net - 39,213 Proceeds from exercise of stock options 163 - Repurchase of unvested restricte	Interest expense (non-cash)		_		107
Deferred contract costs (693) (1,361 Accounts payable 3,904 (154 Accrued expenses and compensation 1,592 237 Deferred revenue 1,100 155 Other liabilities 99 397 Net cash used in operating activities (15,142) (9,332 Cash flows from investing activities (20,573) (11,543 Net cash used in investing activities (20,573) (11,543 Net cash from financing activities (20,573) (11,543 Proceeds from issuance of convertible preferred stock warrants 102 — Proceeds from exercise of convertible preferred stock warrants 102 — Proceeds from the exercise of stock options 163 — Repurchase of unvested restricted common stock (10) —	Changes in operating assets and liabilities:				
Accounts payable Accrued expenses and compensation 1,592 237 Deferred revenue 1,100 155 Other liabilities 99 337 Net cash used in operating activities Purchase of property and equipment (20,573) 1,1543 Net cash used in investing activities Purchase of property and equipment (20,573) 1,1543 Net cash used in investing activities Purchase of property and equipment (20,573) 1,1543 Net cash used in investing activities Proceeds from financing activities Proceeds from investing activities Proceeds from exercise of convertible preferred stock, net Proceeds from exercise of convertible preferred stock warrants 102 Proceeds from exercise of stock options 163 Repurchase of unvested restricted common stock 100 Proceeds from secured promissory notes and converted promissory notes 14,910 1,628 Payments of Business Combination share issuance costs (3,592) Net cash provided by financing activities 11,573 40,841 Change in cash, cash equivalents, and restricted cash 2,218 10,301 Cash and cash equivalents and restricted cash, beginning of period 29,218 10,301 Cash and cash equivalents, and restricted cash, end of period 5,076 5,076 5,073 Supplemental cash flow data (Non-cash): Accrued purchase of property and equipment \$2,298 \$5,053 Accrued purchase of transaction costs Conversion of promissory notes to convertible preferred stock Conversion of	Prepaid expenses and other assets		493		91
Accrued expenses and compensation 1,592 237 Deferred revenue 1,100 155 Other liabilities 99 3397 Net cash used in operating activities (15,142) (9,332 Cash flows from investing activities: Purchase of property and equipment (20,573) (11,543 Net cash used in investing activities (20,573) (11,543 Net cash used in investing activities (20,573) (11,543 Cash flows from financing activities: Proceeds from issuance of convertible preferred stock, net - 39,213 Proceeds from exercise of convertible preferred stock warrants 102 Proceeds from exercise of stock options 163 Repurchase of unvested restricted common stock (10) Proceeds from secured promissory notes and converted promissory notes 14,910 1,628 Payments of Business Combination share issuance costs (3,592) Net cash provided by financing activities 11,573 40,841 Change in cash, cash equivalents, and restricted cash (24,142) 19,966 Cash and cash equivalents and restricted cash, beginning of period 29,218 10,301 Cash and cash equivalents, and restricted cash, end of period \$5,076 \$30,267 Supplemental cash flow data (Non-cash): Accrued purchase of property and equipment \$2,298 \$5,053 Accrued purchase of property and equipment \$2,298 \$5,053 Accrued purchase of property and equipment \$2,298 \$5,053 Accrued purchase of property and equipment \$2,238 \$ Conversion of promissory notes to convertible preferred stock Conversion of promissory notes to convertible preferred stock Settlement of accrued interest expense through conversion of promissory notes to convertible preferred stock Conversion of promissory notes to convertible preferred stock Convertib	Deferred contract costs		(693)		(1,361)
Deferred revenue1,100155Other liabilities99397Net cash used in operating activities(15,142)(9,332)Cash flows from investing activities:Purchase of property and equipment(20,573)(11,543)Net cash used in investing activities(20,573)(11,543)Cash flows from financing activities:(20,573)(11,543)Proceeds from issuance of convertible preferred stock, net—39,213Proceeds from exercise of convertible preferred stock warrants102—Proceeds from the exercise of stock options163—Repurchase of unvested restricted common stock(10)—Proceeds from secured promissory notes and converted promissory notes14,9101,628Payments of Business Combination share issuance costs(3,592)—Net cash provided by financing activities11,57340,841Change in cash, cash equivalents, and restricted cash(24,142)19,966Cash and cash equivalents and restricted cash, beginning of period29,21810,301Cash and cash equivalents, and restricted cash, end of period\$ 5,076\$ 30,267Supplemental cash flow data (Non-cash):Accrued purchase of property and equipment\$ 2,298\$ 5,053Accrued purchase of property and equipment\$ 2,298\$ 5,053Accrued purchase of transaction costs2,133—Conversion of promissory notes to convertible preferred stock— 8,073Settlement of accrued interest expense through conversion of promissory notes to <td>Accounts payable</td> <td></td> <td>3,904</td> <td></td> <td>(154)</td>	Accounts payable		3,904		(154)
Other liabilities99397Net cash used in operating activities(15,142)(9,332)Cash flows from investing activities:20,573(11,543)Purchase of property and equipment(20,573)(11,543)Net cash used in investing activities:20,573(11,543)Proceeds from financing activities:39,213Proceeds from issuance of convertible preferred stock, net-39,213Proceeds from exercise of convertible preferred stock warrants102-Proceeds from the exercise of stock options163-Repurchase of unvested restricted common stock(10)-Proceeds from secured promissory notes and converted promissory notes14,9101,628Payments of Business Combination share issuance costs(3,592)-Net cash provided by financing activities11,57340,841Change in cash, cash equivalents, and restricted cash(24,142)19,966Cash and cash equivalents and restricted cash, beginning of period29,21810,301Cash and cash equivalents, and restricted cash, beginning of period29,21810,301Cash and cash equivalents, and restricted cash, end of period\$ 5,076\$ 30,267Supplemental cash flow data (Non-cash):Accrued purchase of transaction costs2,133-Conversion of promissory notes to convertible preferred stock-8,073Settlement of accrued interest expense through conversion of promissory notes to-8,073Settlement of accrued interest expense through conversion of promissory not	Accrued expenses and compensation		1,592		237
Net cash used in operating activities (15,142) (9,332) Cash flows from investing activities: Purchase of property and equipment (20,573) (11,543) Net cash used in investing activities (20,573) (11,543) Cash flows from financing activities: Proceeds from fisuance of convertible preferred stock, net - 39,213 Proceeds from exercise of convertible preferred stock warrants 102 Proceeds from the exercise of stock options 163 Repurchase of unvested restricted common stock (10) Proceeds from secured promissory notes and converted promissory notes 14,910 1,628 Payments of Business Combination share issuance costs (3,592) Net cash provided by financing activities 11,573 40,841 Change in cash, cash equivalents, and restricted cash (24,142) 19,966 Cash and cash equivalents and restricted cash, beginning of period 29,218 10,301 Cash and cash equivalents, and restricted cash, end of period \$5,076 \$30,267 Supplemental cash flow data (Non-cash): Accrued purchase of property and equipment \$2,298 \$5,053 Accrued purchase of transaction costs 2,133 Conversion of promissory notes to convertible preferred stock Settlement of accrued interest expense through conversion of promissory notes to convertible preferred stock Convertible preferred stock South through the control of promissory notes to convertible preferred stock Convertible preferred stock South through the control of promissory notes to convertible preferred stock Convertible prefer	Deferred revenue		1,100		155
Cash flows from investing activities: Purchase of property and equipment (20,573) (11,543) Net cash used in investing activities (20,573) (11,543) Cash flows from financing activities: Proceeds from fissuance of convertible preferred stock, net - 39,213 Proceeds from exercise of convertible preferred stock warrants 102 Proceeds from the exercise of stock options 163 Repurchase of unvested restricted common stock (10) Proceeds from secured promissory notes and converted promissory notes 14,910 1,628 Payments of Business Combination share issuance costs (3,592) Net cash provided by financing activities 11,573 40,841 Change in cash, cash equivalents, and restricted cash (24,142) 19,966 Cash and cash equivalents and restricted cash, beginning of period 29,218 10,301 Cash and cash equivalents, and restricted cash, end of period \$5,076 \$30,267 Supplemental cash flow data (Non-cash): Accrued purchase of property and equipment \$2,298 \$5,053 Accrued purchase of transaction costs 2,133 Recrued purchase of transaction costs 2,133 Recrued purchase of property and equipment (20,000) and convertible preferred stock (20,000) and convertible preferred	Other liabilities		99		397
Cash flows from investing activities: Purchase of property and equipment (20,573) (11,543) Net cash used in investing activities (20,573) (11,543) Cash flows from financing activities: Proceeds from fissuance of convertible preferred stock, net - 39,213 Proceeds from exercise of convertible preferred stock warrants 102 Proceeds from the exercise of stock options 163 Repurchase of unvested restricted common stock (10) Proceeds from secured promissory notes and converted promissory notes 14,910 1,628 Payments of Business Combination share issuance costs (3,592) Net cash provided by financing activities 11,573 40,841 Change in cash, cash equivalents, and restricted cash (24,142) 19,966 Cash and cash equivalents and restricted cash, beginning of period 29,218 10,301 Cash and cash equivalents, and restricted cash, end of period \$5,076 \$30,267 Supplemental cash flow data (Non-cash): Accrued purchase of property and equipment \$2,298 \$5,053 Accrued purchase of transaction costs 2,133 Recrued purchase of transaction costs 2,133 Recrued purchase of property and equipment (20,000) and convertible preferred stock (20,000) and convertible preferred	Net cash used in operating activities		(15,142)		(9,332)
Purchase of property and equipment (20,573) (11,543) Net cash used in investing activities (20,573) (11,543) Cash flows from financing activities: Proceeds from issuance of convertible preferred stock, net — 39,213 Proceeds from exercise of convertible preferred stock warrants 102 — Proceeds from the exercise of stock options 163 — Repurchase of unvested restricted common stock (10) — Proceeds from secured promissory notes and converted promissory notes 14,910 1,628 Payments of Business Combination share issuance costs (3,592) — Net cash provided by financing activities 11,573 40,841 Change in cash, cash equivalents, and restricted cash to equivalents, and restricted cash (24,142) 19,966 Cash and cash equivalents, and restricted cash, beginning of period 29,218 10,301 Cash and cash equivalents, and restricted cash, end of period \$5,076 \$30,267 Supplemental cash flow data (Non-cash): Accrued purchase of property and equipment \$2,298 \$5,053 Accrued purchase of property and equipment \$2,298 \$5,053 Accrued purchase of transaction costs 2,133 — 80,073 Settlement of accrued interest expense through conversion of promissory notes to convertible preferred stock — 80,073 Settlement of accrued interest expense through conversion of promissory notes to convertible preferred stock — 80,073	Cash flows from investing activities:			-	
Net cash used in investing activities (20,573) (11,543) Cash flows from financing activities: Proceeds from issuance of convertible preferred stock, net - 39,213 Proceeds from exercise of convertible preferred stock warrants 102 Proceeds from the exercise of stock options 163 Repurchase of unvested restricted common stock (10) Proceeds from secured promissory notes and converted promissory notes 14,910 1,628 Payments of Business Combination share issuance costs (3,592) Net cash provided by financing activities 11,573 40,841 Change in cash, cash equivalents, and restricted cash (24,142) 19,966 Cash and cash equivalents and restricted cash, beginning of period 29,218 10,301 Cash and cash equivalents, and restricted cash, end of period \$5,076 \$30,267 Supplemental cash flow data (Non-cash): Accrued purchase of property and equipment \$2,298 \$5,053 Accrued purchase of transaction costs 2,133 Conversion of promissory notes to convertible preferred stock Settlement of accrued interest expense through conversion of promissory notes to convertible preferred stock Convertible preferred stock Source the flow data (Non-cash): Accrued purchase of transaction costs Convertible preferred stock Convertible preferred stock Source	·		(20,573)		(11,543)
Cash flows from financing activities: Proceeds from issuance of convertible preferred stock, net Proceeds from exercise of convertible preferred stock warrants Proceeds from exercise of stock options Repurchase of unvested restricted common stock Proceeds from secured promissory notes and converted promissory notes Payments of Business Combination share issuance costs Repurchase of unvested promissory notes and converted promissory notes Payments of Business Combination share issuance costs Repurchase of unvested promissory notes and converted promissory notes Payments of Business Combination share issuance costs Repurchase of growing activities Supplemental cash quivalents, and restricted cash, beginning of period Supplemental cash flow data (Non-cash): Accrued purchase of property and equipment \$ 2,298 \$ 5,053 Accrued purchase of transaction costs Conversion of promissory notes to convertible preferred stock - 8,073 Settlement of accrued interest expense through conversion of promissory notes to convertible preferred stock - 130					
Proceeds from issuance of convertible preferred stock, net Proceeds from exercise of convertible preferred stock warrants Proceeds from the exercise of stock options Repurchase of unvested restricted common stock Repurchase of unvested restricted common stock Proceeds from secured promissory notes and converted promissory notes Payments of Business Combination share issuance costs Ret cash provided by financing activities Net cash provided by financing activities Repurchase of unvested restricted cash Repurchase of Business Combination share issuance costs Ret cash provided by financing activities Repurchase of Business Combination of States and Cash (10) Repurchase of Business Combination of States and Cash (10) Repurchase of Business Combination of States and Cash (10) Repurchase of Lagona Activities Repurchase of Itas (10) Repurchase of States and Cash (10) Repurchase of Itas (· ·	-			
Proceeds from exercise of convertible preferred stock warrants Proceeds from the exercise of stock options Repurchase of unvested restricted common stock Repurchase of unvested restricted common stock Proceeds from secured promissory notes and converted promissory notes 14,910 1,628 Payments of Business Combination share issuance costs Ret cash provided by financing activities Net cash provided by financing activities 11,573 40,841 Change in cash, cash equivalents, and restricted cash Cash and cash equivalents and restricted cash, beginning of period 29,218 10,301 Cash and cash equivalents, and restricted cash, end of period Supplemental cash flow data (Non-cash): Accrued purchase of property and equipment \$ 2,298 \$ 5,053 Accrued purchase of transaction costs Conversion of promissory notes to convertible preferred stock - 8,073 Settlement of accrued interest expense through conversion of promissory notes to convertible preferred stock - 130			_		39.213
Proceeds from the exercise of stock options Repurchase of unvested restricted common stock Repurchase of unvested restricted common stock Proceeds from secured promissory notes and converted promissory notes 14,910 1,628 Payments of Business Combination share issuance costs (3,592) Net cash provided by financing activities 11,573 40,841 Change in cash, cash equivalents, and restricted cash Cash and cash equivalents and restricted cash, beginning of period 29,218 10,301 Cash and cash equivalents, and restricted cash, end of period \$5,076 Supplemental cash flow data (Non-cash): Accrued purchase of property and equipment \$2,298 \$5,053 Accrued purchase of transaction costs Conversion of promissory notes to convertible preferred stock - 8,073 Settlement of accrued interest expense through conversion of promissory notes to convertible preferred stock - 130	·		102		_
Repurchase of unvested restricted common stock Proceeds from secured promissory notes and converted promissory notes Payments of Business Combination share issuance costs Net cash provided by financing activities Net cash provided by financing activities Cash and cash equivalents, and restricted cash Cash and cash equivalents and restricted cash, beginning of period Cash and cash equivalents, and restricted cash, end of period Supplemental cash flow data (Non-cash): Accrued purchase of property and equipment Accrued purchase of transaction costs Conversion of promissory notes to convertible preferred stock Conversion of professory notes to convertible preferred stock Convertible preferred stock Cash and cash equivalents, and restricted cash, end of period Supplemental cash flow data (Non-cash): Accrued purchase of property and equipment \$ 2,298 \$ 5,053 Accrued purchase of transaction costs Conversion of promissory notes to convertible preferred stock — 8,073 Settlement of accrued interest expense through conversion of promissory notes to convertible preferred stock — 130					_
Proceeds from secured promissory notes and converted promissory notes Payments of Business Combination share issuance costs Net cash provided by financing activities Net cash provided by financing activities Change in cash, cash equivalents, and restricted cash Cash and cash equivalents and restricted cash, beginning of period Cash and cash equivalents, and restricted cash, end of period Payella 10,301 Cash and cash equivalents, and restricted cash, end of period Supplemental cash flow data (Non-cash): Accrued purchase of property and equipment Accrued purchase of transaction costs Conversion of promissory notes to convertible preferred stock Conversion of promissory notes to convertible preferred stock Convertible preferred stock - 130			(10)		_
Payments of Business Combination share issuance costs Net cash provided by financing activities 11,573 40,841 Change in cash, cash equivalents, and restricted cash Cash and cash equivalents and restricted cash, beginning of period 29,218 10,301 Cash and cash equivalents, and restricted cash, end of period \$5,076 \$30,267 Supplemental cash flow data (Non-cash): Accrued purchase of property and equipment \$2,298 \$5,053 Accrued purchase of transaction costs Conversion of promissory notes to convertible preferred stock - 8,073 Settlement of accrued interest expense through conversion of promissory notes to convertible preferred stock - 130					1,628
Net cash provided by financing activities Change in cash, cash equivalents, and restricted cash Cash and cash equivalents and restricted cash, beginning of period Cash and cash equivalents, and restricted cash, beginning of period Cash and cash equivalents, and restricted cash, end of period Supplemental cash flow data (Non-cash): Accrued purchase of property and equipment Accrued purchase of transaction costs Conversion of promissory notes to convertible preferred stock Settlement of accrued interest expense through conversion of promissory notes to convertible preferred stock - 130					_
Change in cash, cash equivalents, and restricted cash Cash and cash equivalents and restricted cash, beginning of period Cash and cash equivalents, and restricted cash, beginning of period Cash and cash equivalents, and restricted cash, end of period Supplemental cash flow data (Non-cash): Accrued purchase of property and equipment \$ 2,298 \$ 5,053 Accrued purchase of transaction costs Conversion of promissory notes to convertible preferred stock Conversion of accrued interest expense through conversion of promissory notes to convertible preferred stock Convertible preferred stock - 130	,				40.841
Cash and cash equivalents and restricted cash, beginning of period 29,218 10,301 Cash and cash equivalents, and restricted cash, end of period \$5,076 \$30,267 \$30,267 \$\$\$ Supplemental cash flow data (Non-cash): Accrued purchase of property and equipment \$2,298 \$5,053 \$\$\$ Accrued purchase of transaction costs 2,133 — Conversion of promissory notes to convertible preferred stock — 8,073 \$\$\$\$ Settlement of accrued interest expense through conversion of promissory notes to convertible preferred stock — 130	· · · ·				
Cash and cash equivalents, and restricted cash, end of period \$ 5,076 \$ 30,267 Supplemental cash flow data (Non-cash): Accrued purchase of property and equipment \$ 2,298 \$ 5,053 Accrued purchase of transaction costs 2,133 — Conversion of promissory notes to convertible preferred stock — 8,073 Settlement of accrued interest expense through conversion of promissory notes to convertible preferred stock — 130					
Supplemental cash flow data (Non-cash): Accrued purchase of property and equipment \$ 2,298 \$ 5,053 Accrued purchase of transaction costs 2,133 — Conversion of promissory notes to convertible preferred stock — 8,073 Settlement of accrued interest expense through conversion of promissory notes to convertible preferred stock — 130		\$		\$	
Accrued purchase of property and equipment \$ 2,298 \$ 5,053 Accrued purchase of transaction costs 2,133 — Conversion of promissory notes to convertible preferred stock — 8,073 Settlement of accrued interest expense through conversion of promissory notes to convertible preferred stock — 130	cash and cash equivalents, and restricted easily end of period	<u> </u>	3,070	<u>~</u>	30,207
Accrued purchase of property and equipment \$ 2,298 \$ 5,053 Accrued purchase of transaction costs 2,133 — Conversion of promissory notes to convertible preferred stock — 8,073 Settlement of accrued interest expense through conversion of promissory notes to convertible preferred stock — 130	Supplemental cash flow data (Non-cash):				
Accrued purchase of transaction costs 2,133 — Conversion of promissory notes to convertible preferred stock — 8,073 Settlement of accrued interest expense through conversion of promissory notes to convertible preferred stock — 130		\$	2,298	\$	5,053
Conversion of promissory notes to convertible preferred stock — 8,073 Settlement of accrued interest expense through conversion of promissory notes to convertible preferred stock — 130					_
Settlement of accrued interest expense through conversion of promissory notes to convertible preferred stock — 130	•				8,073
convertible preferred stock — 130	· · ·				-,,,
·	· · · · · · · · · · · · · · · · · · ·		_		130
	Issuance of convertible preferred stock warrants		_		1,476

Net Loss to Adjusted EBITDA

While we prepare our condensed consolidated financial statements in accordance with GAAP, we also utilize and present certain financial measures that are not based on GAAP. We refer to these financial measures as "Non-GAAP" financial measures. In addition to our financial results determined in accordance with GAAP, we believe that EBITDA and Adjusted EBITDA are useful measures in evaluating its financial and operational performance distinct and apart from financing costs, certain non-cash expenses and non-operational expenses.

These Non-GAAP financial measures should be considered in addition to results prepared in accordance with GAAP but should not be considered a substitute for or superior to GAAP. We endeavor to compensate for the limitation of the Non-GAAP financial measures presented by also providing the most directly comparable GAAP measures.

We use Non-GAAP financial information to evaluate our ongoing operations and for internal planning, budgeting

and forecasting purposes. We believe that Non-GAAP financial information, when taken collectively, may be helpful to investors in assessing its operating performance and comparing its performance with competitors and other comparable companies. You should review the reconciliations below but not rely on any single financial measure to evaluate our business.

"EBITDA" is defined as earnings (net loss) adjusted for interest expense; income taxes; depreciation expense, and amortization expense. "Adjusted EBITDA" includes additional adjustments to EBITDA such as stock-based compensation expense; change in fair value of convertible preferred stock warrants and convertible promissory notes; and other special items as determined by management which it does not believe to be indicative of its underlying business trends.

Below is a reconciliation of net loss on a GAAP basis to the Non-GAAP EBITDA and Adjusted EBITDA financial measures for the periods presented below:

	T	Three Months Ended June 30,			Six Months Ende			ed June 30,	
		2021		2020		2021		2020	
Net loss	\$	(14,303)	\$	(5,150)	\$	(30,468)	\$	(12,832)	
Interest expense		135		_		135		107	
Depreciation and amortization		234		145		375		289	
EBITDA		(13,934)		(5,005)		(29,958)		(12,436)	
Stock-based compensation		2,120		58		3,675		116	
Change in fair value of convertible									
preferred stock warrants		_		(209)		4,781		(275)	
Issuance of convertible preferred stock									
warrants		_		_		_		1,476	
Change in fair value of convertible									
promissory notes		_						2,422	
Adjusted EBITDA	\$	(11,814)	\$	(5,156)	\$	(21,502)	\$	(8,697)	

Free Cash Flow

Below is a reconciliation of Net cash used in operating activities to the Free Cash Flow financial measures for the periods presented below (in thousands):

	Six Months Ended June 30,								
		2020							
Net cash used in operating activities	\$	(15,142)	\$	(9,332)					
Capital (expenditures)		(20,573)		(11,543)					
Free Cash Flow (1)	\$	(35,715)	\$	(20,875)					

(1) We define "Free Cash Flow" as (i) Net cash from operating activities less (ii) capital expenditures, net of proceeds from disposals of property and equipment, all of which are derived from Legacy Enovix's condensed consolidated statements of cash flow. The presentation of non-GAAP Free Cash Flow is not intended as an alternative measure of cash flows from operations, as determined in accordance with GAAP. We believe that this financial measure is useful to investors because it provides investors to view our performance using the same tool that we use to gauge our progress in achieving our goals and it is an indication of cash flow that may be available to fund investments in future growth initiatives.



Management's Use of Non-GAAP Financial Measures

EBITDA, Adjusted EBITDA and Free Cash Flow are intended as supplemental financial measures of Enovix's performance that are neither required by, nor presented in accordance with GAAP. Enovix believes that the use of EBITDA, Adjusted EBITDA and Free Cash Flow provides an additional tool for investors to use in evaluating ongoing operating results, trends, and in comparing its financial measures with those of comparable companies, which may present similar Non-GAAP financial measures to investors.

However, you should be aware that when evaluating EBITDA, Adjusted EBITDA, and Free Cash Flow, Enovix may incur future expenses similar to those excluded when calculating these measures. In addition, the presentation of these measures should not be construed as an inference that its future results will be unaffected by unusual or nonrecurring items. Enovix's computation of EBITDA, Adjusted EBITDA, and Free Cash Flow may not be comparable to other similarly titled measures computed by other companies, because all companies may not calculate EBITDA, Adjusted EBITDA and Free Cash Flow in the same fashion.

Forward-Looking Statements

This letter to shareholders contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, about us and our industry that involve substantial risks and uncertainties. Forward-looking statements generally relate to future events or Enovix's future financial or operating performance. In some cases, you can identify forwardlooking statements because they contain words such as "believe", "will", "may", "estimate", "continue", "anticipate", "intend", "should", "plan", "expect", "predict", "could", "potentially", "target", "project", "believe", "continue" or the negative of these terms or similar expressions. Forwardlooking statements in this letter to shareholders include. but are not limited to, statements regarding our financial and business performance, our ability to meet milestones and deliver on our objectives and expectations, our ability to scale, our use of proceeds from the business combination with RSVAC, statements regarding our planned investments and the potential returns on those investments, the future demand for our lithium-ion battery solutions, our ability to achieve market acceptance for our products, the implementation and success of our business model and growth strategy, statements regarding our expectations regarding market opportunity and the expansion of our customer base, and our ability to meet the expectations of new and current customers. Actual results could differ materially from these forward-looking statements as a result of certain risks and uncertainties, including, without limitation, the risks set forth under the caption "Risk Factors" in the Registration Statement on Form S-1 (No. 333-258358) that Enovix filed with the Securities and Exchange Commission (the "SEC") on August 2, 2021, and other documents Enovix has filed, or that Enovix will file, with the SEC. Any forward-looking statements made by Enovix in this letter to shareholders speak only as of the date on which they are made and subsequent events may cause these expectations to change. Enovix disclaims any obligations to update or alter these forward-looking statements in the future, whether as a result of new information, future events or otherwise, except as required by law.

